Late-Breaking Sessions

AACC has added the following late-breaking session to the scientific meeting schedule.

Theranos Whistleblowers - Erika Cheung and Tyler Shultz

Fireside Chat with Theranos Whistleblowers Erika Cheung and Tyler Shultz

Tuesday, July 26
1 p.m. U.S. Central Time
Room S100
McCormick Place Convention Center

Erika Cheung and Tyler Shultz—two of the key whistleblowers who helped bring down Theranos—will speak in a special fireside chat. In this session, Cheung and Shultz will discuss the ethical challenges they faced in their efforts to reveal Theranos’ fraud and protect patients from the company’s faulty tests.

After Theranos launched its retail testing service in 2013, it quickly gained national prominence with its promise of revolutionizing the way lab testing works in the U.S. However, when laboratory experts were finally able to evaluate Theranos’ actual science at the 2016 AACC Annual Scientific Meeting, Theranos CEO Elizabeth Holmes was unable to dispel suspicions that she was lying about her technology’s capabilities.

Cheung and Shultz worked with fellow whistleblowers to reveal—both to federal regulators and the press—that the Theranos laboratory actively put patients at risk of misdiagnosis and harm by offering them unreliable tests. Cheung later testified at Holmes’ trial as well. It is in large part thanks to the courage of these whistleblowers that Theranos was shut down and Holmes convicted of fraud.

Cheung and Shultz will discuss their experience with getting the truth out about Theranos on July 26 at the 2022 AACC Annual Scientific Meeting. Specifically, they will focus on the ethics of the situation they found themselves in at Theranos, as well as the overall ethical obligations of clinical laboratories and the vital role laboratory medicine professionals play in keeping patients safe. The discussion will be moderated by AACC President Dr. Stephen R. Master, who himself served as an expert witness in Elizabeth Holmes’ trial.

Register for 2022 AACC

Join us in Chicago, July 24-28 to explore the cutting-edge science and technology shaping the future of laboratory medicine.